James Baker is a Rheumatology/Immunology physician. ClinicalTrials.gov lists 2 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Research metrics aren't shown for this record. Either we found no confident publication match for this name, or more than one physician shares the matched author record. We'd rather show nothing than someone else's numbers. Why? →
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
9495 SW Locust St Ste A
Portland, OR 972236683
Telephone
503-636-9011Registry record last updated 28 Jul 2015.
Clinical trials
- COVID19 SARS Vaccinations: Systemic Allergic Reactions to SARS-CoV-2 Vaccinations
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
22 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- CSL BehringProgram year202514 payments
- GENZYME CORPORATIONProgram year202511 payments
- Galderma Laboratories, L.P.Program year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Respiratory
92.2%Anti-IgE63.2%Omalizumab96%Xolair4%Part D + Part B<11 patientsCorticosteroid13.5%Arnuity Ellipta26%Trelegy Ellipta16%Budesonide-Formoterol Fumarate11%Breo Ellipta11%Fluticasone Propionate Hfa8%Fluticasone Propionate6%Symbicort6%Breyna6%Qvar Redihaler6%Dulera5%Part D<11 patients+ 7 more classes in this area
Dermatology
3.4%Interleukin-4 Receptor alpha Antagonist2.3%Dupixent Syringe64%Dupixent Pen36%Part D<11 patientsCorticosteroid1.1%Triamcinolone Acetonide100%Part D≥19 patientsMetabolism & gastrointestinal
1.6%Corticosteroid1.3%Prednisone100%Part D≥23 patientsH2 blocker0.4%Famotidine100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Similar KOLs
Other experts from the same institution or the same specialty.
David J. Hunter
The University of Sydney
Aziz Sheikh
Universiti Malaysia Terengganu
Nima Hafezi‐Nejad
The University of Sydney
Gelin Xu
Second Affiliated Hospital of Nanjing Medical University
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”